Open AccessComment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia”
Author(s) -
Danilo Perrotti,
Anupriya Agarwal,
Claire Lucas,
Goutham Narla,
Paolo Neviani,
María D. Odero,
Peter P. Ruvolo,
Nicole M. Verrills
Publication year - 2019
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.aau0416
Subject(s) - tyrosine kinase , cancer research , abl , leukemia , stem cell , medicine , chemistry , biology , microbiology and biotechnology , receptor
LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom